amyotrophic lateral sclerosis

(redirected from Riluzole)
Also found in: Thesaurus, Medical, Encyclopedia, Wikipedia.

a·my·o·tro·phic lateral sclerosis

 (ā′mī-ə-trō′fĭk, -trŏf′ĭk, ā-mī′-)
n. Abbr. ALS
A chronic, progressive disease marked by gradual degeneration of the nerve cells in the spinal cord that control voluntary muscle movement, causing muscle weakness, atrophy, and eventual paralysis. Also called Lou Gehrig's disease.
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

amyotrophic lateral sclerosis

(Pathology) a form of motor neurone disease in which degeneration of motor tracts in the spinal cord causes progressive muscular paralysis starting in the limbs. Also called: Lou Gehrig's disease
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014

a•my•o•troph′ic lat′eral sclero′sis

(ˌeɪ maɪ əˈtrɒf ɪk, -ˈtroʊ fɪk, eɪˌmaɪ ə-)
a nervous system disease in which degeneration of motor neurons in the brain stem and spinal cord leads to atrophy and paralysis of the voluntary muscles. Abbr.: ALS Also called Lou Gehrig's disease.
[1885–90; a-6 + myo- + -trophic]
Random House Kernerman Webster's College Dictionary, © 2010 K Dictionaries Ltd. Copyright 2005, 1997, 1991 by Random House, Inc. All rights reserved.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.amyotrophic lateral sclerosis - thickening of tissue in the motor tracts of the lateral columns and anterior horns of the spinal cordamyotrophic lateral sclerosis - thickening of tissue in the motor tracts of the lateral columns and anterior horns of the spinal cord; results in progressive muscle atrophy that starts in the limbs
nervous disorder, neurological disease, neurological disorder - a disorder of the nervous system
induration, sclerosis - any pathological hardening or thickening of tissue
Based on WordNet 3.0, Farlex clipart collection. © 2003-2012 Princeton University, Farlex Inc.
References in periodicals archive ?
[sup][28] found that the ZNF512B gene was a new prognostic factor for ALS, independent of gender, age, time from onset to diagnosis, site of symptom onset (bulbar/spinal cord), and treatment with riluzole. However, the study was based on a small sample of 176 patients, and they obtained different results from the original research of Iida et al.
Lurasidone * Latuda Mirtazapine * Remeron Moclobemide * Amira, Aurorix, Clobemix, Depnil, Manerix Modafinil * Provigil Olanzapine/fluoxetine * Symbyax Paroxetine * Paxil Phenelzine * Nardil Pramipexole * Mirapex Quetiapine * Seroquel Riluzole * Rilutek Sertraline * Zoloft Vortioxetine * Brintellix
Trophos SA says the results from the Phase III study of its lead compound, olesoxime, did not demonstrate a significant increase in survival versus placebo in 512 patients with ALS also receiving riluzole (Rilutek[R]).
at Harvard University (reported in Nature Medicine), mice treated with creatine had a longer survival than those treated with riluzole. It is thought the creatine stabilizes mitochondrial enzymes, thereby slowing cell death.
"They'll go anywhere to get it," he says, adding that he remains deeply skeptical about the drug, riluzole. Indeed, Rowland tells his patients he doesn't believe the drug will work.
The presentation entitled "Ibudilast - Phosphodiesterase Type 4 Inhibitor - Bi-Modal Therapy with Riluzole in Early Cohort and Advanced Amyotrophic Lateral Sclerosis Patients - Single-Center Adaptive Design Six-Month Double-Blind - Placebo-Controlled Phase 1b/2a Epoch Followed by Six-Month Open Label Extension Epoch, Washout and Post-Washout Epoch - Final Report and Future Directions" will be available for review throughout the afternoon on April 27th.
The company said BHV-0223 is an innovative sublingually administered and orally dissolving tablet (ODT) formulation of riluzole, a glutamate modulating agent, which is designed to advance beyond the current limitations of riluzole tablets.
At the time of the investigation, none of the patients were taking riluzole or any antispasticity drugs.
These new grants focus on understanding how the new genes TDP43 and FUS contribute to disease, development of a novel model system to understand neuronal activity, immune mechanisms in ALS, and development of novel Riluzole (Rilutek) derivatives with improved activity.
They include riluzole, a drug used to treat ALS ("Lou Gehrig's disease"), and the cannabis derivative dronabinol.
In 1995, riluzole (Rilutek[R]) was approved by the Food and Drug Administration (FDA) for management of ALS.[11] This article reviews the mechanism of action, pharmacokinetics, contraindications and warnings, dosage, administration and nursing implications of riluzole.